OPKO Health, Inc. Current Assets
OPKO Health, Inc. (OPK) had Current Assets of $500.24 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-28
- 2026-06-30: Assets, Current $500.24M.
- 2026-03-31: Assets, Current $535.36M.
- 2025-12-31: Assets, Current $581.88M.
- 2025-09-30: Assets, Current $627.13M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $500.24M 10-Q/A · filed 2026-08-28 | |
| 2026-03-31 | $535.36M 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $581.88M 10-Q/A · filed 2026-08-28 | |
| 2025-09-30 | $627.13M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $583.33M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $737.60M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $662.09M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $629.64M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $357.98M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $391.30M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $309.48M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $357.24M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $433.79M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $406.42M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $394.52M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $413.97M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $494.75M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $754.07M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $823.01M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $557.51M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $547.03M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $599.05M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $523.18M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $428.11M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $360.05M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $274.46M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $324.05M 10-K · filed 2021-02-18 | |
| 2019-09-30 | $292.84M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $344.23M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $435.24M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $317.73M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $289.82M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $321.56M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $349.35M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $348.86M 10-K · filed 2019-03-01 | $343.46M 10-K · filed 2018-03-01 |
| 2017-09-30 | $430.56M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $472.52M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $459.93M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $483.60M 8-K · filed 2019-01-29 | |
| 2016-09-30 | $502.07M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $505.57M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $453.53M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $454.06M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $517.42M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $278.34M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $394.02M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $142.87M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $163.15M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $183.01M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $205.27M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $242.73M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $241.28M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $230.12M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $237.68M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $78.66M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $87.98M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $92.35M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $99.41M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $99.58M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $117.63M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $127.63M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $57.39M 10-K · filed 2012-03-15 | $54.07M 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |